Cholangiocarcinoma

Researchers aimed to assess characteristics, outcomes, and genomic profiles of long-term survivors treated with durvalumab plus gemcitabine/cisplatin (GemCis) or placebo plus GemCis in the TOPAZ-1 trial.

IMbrave 151 examined the efficacy of the PD-L1 inhibitor atezolizumab with or without the VEGF inhibitor bevacizumab, and gemcitabine/cisplatin as first-line treatments in patients with advanced biliary tract cancer.

A single-arm, phase 2 study investigated the safety and efficacy of second-line nab-paclitaxel combined with the anti–PD-1 antibody sintilimab in patients with advanced biliary tract cancer.

This phase 2 randomized trial assessed stereotactic body radiation and the anti–PD-1 drug nivolumab with or without the anti-CTLA4 drug ipilimumab in patients with metastatic biliary tract cancer.

This study examined the costs of treatment with gemcitabine/cisplatin with or without durvalumab in patients with advanced cholangiocarcinoma.

In the phase 3 Nutide:121 study, NUC-1031 plus cisplatin was compared with gemcitabine/cisplatin for first-line treatment of patients with advanced biliary tract cancer.

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.

Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma.

Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.